Glycogen synthase kinase-3 β activity and cognitive functioning in patients with bipolar I disorder

Cognitive deficits are common in patients with bipolar disorder (BD) in remission and may be associated with glycogen synthase kinase-3 (GSK-3) activity, which is inhibited by lithium. GSK-3 may be a relevant treatment target for interventions tailored at cognitive disturbances in BD but the relation between GSK-3 activity, cognition and lithium treatment is unknown. We therefore investigated the possible association between GSK-3 activity and cognition and whether lithium treatment moderates this association in patients with BD.

Source: European Neuropsychopharmacology - February 10, 2018 Category: Psychiatry & Psychology Authors: Klaus Munkholm, Kamilla Woznica Miskowiak, Anne Sophie Jacoby, Maj Vinberg, Leda Leme Talib, Wagner Farid Gattaz, Lars Vedel Kessing Source Type: research